• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix launches another pivotal for Dextenza eye drug-device combo

November 24, 2015 By Brad Perriello

Ocular TherapeutixOcular Therapeutix (NSDQ:OCUL) said today that it launched another pivotal trial for its Dextenza drug-device combination, its 2nd study of the treatment for an allergic conjunctivitis indication.

Bedford, Mass.-based Ocular Therapeutix has had mixed results with Dextenza, formerly known as OTX-DP, which is designed to deliver sustained dosage of dexamethasone over 4 weeks, using a hydrogel plug inserted into a tear duct. The plug then dissolves and is flushed from the body as tears.

In March, Ocular said a 1st, 247-patient trial examining Dextenza for reducing pain and inflammation after cataract surgery showed that 33.7% of the Dextenza arm showed no inflammatory cells after 14 days, compared to 14.6% for the placebo control arm. Some 76.1% of patients receiving the drug reported no pain after 8 days, compared to 36.1% of the placebo arm.

But Dextenza failed to meet a key endpoint the 2nd clinical trial for the pain & inflammation indication, the company said in April. The 240-patient trial met its pain endpoint but missed the inflammation endpoint. Although 77.5% of patients in the Dextenza arm reported no pain after 8 days, compared with 58.8% of the control arm, the difference in inflammatory cell counts after 14 days was not statistically significant (39.4% vs. 31.3%), the company said, noting that both endpoints had to be met to consider the study a success.

Founder & CEO Amar Sawhney said Ocular is also pursuing a new drug application for Dextenza in treating post-surgical ocular pain; top-line results from a Phase II study for inflammatory dry eye are expected before the end of the year, Sawhney said.

“The start of another Phase III clinical trial for Dextenza demonstrates our commitment to applying our proprietary, hydrogel platform to additional indications where patients can benefit from sustained-release therapies,” he said. “We are pleased to advance the Dextenza platform in allergic conjunctivitis, with the goal of providing patients with one-time, seasonal therapy that is preservative-free. For the first time, Dextenza offers the potential for full-season relief to the patient, as a product candidate designed to both treat ocular itching for 4 weeks and offer prophylaxis against allergic conjunctivitis.”

The new allergic conjunctivitis trial is designed to compare Dextenza with a placebo using 4 series of allergen challenges over 30 days, with the treatment or control administered 48 to 72 hours after exposure. The sole primary endpoint is ocular itching at day 7, Ocular said.

Top-line data from the 1st allergic conjunctivitis Phase III, released last month, showed that Dextenza met the primary endpoint of itching. The trial failed to meet the 2nd endpoint, conjunctival redness, although the company noted at the time that FDA hasn’t required conjunctival redness for approval in other allergic conjunctivitis trials.

If Dextenza meets the itching endpoint in the 2nd trial, Ocular said it expects to submit an NDA to the FDA for an indication of ocular itching associated with allergic conjunctivitis (depending on how things go for the post-surgical pain NDA, that is).

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS